Jenscare Scientific Co., Ltd. (9877) has announced the receipt of registration approval from the New Zealand Medicines and Medical Devices Safety Authority for its Ken-Valve transcatheter aortic valve replacement system and LuX-Valve Plus transcatheter tricuspid valve replacement system.

The company is promoting the commercialization of these two products in New Zealand. According to the announcement, design advantages, ongoing registration clinical trials, and active treatment promotion initiatives have contributed to the widespread market recognition of Ken-Valve and LuX-Valve Plus.

Following the approval, the company intends to accelerate global commercialization of its product portfolio. However, there is no assurance of ultimately marketing them successfully, and shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.